Differential Dynamic Behavior of Prefusion Spike Glycoproteins of Sars Coronaviruses 1 and 2
by Moradi, Mahmoud; Kumar, Vivek Govind; Ogden, Dylan S.; Isu, Ugochi; Losey, James
Within the last two decades, severe acute respiratory syndrome (SARS) coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2) have caused two major outbreaks. For reasons yet to be fully understood, the COVID-19 outbreak caused by SARS-CoV-2 has been significantly more widespread than the 2003 SARS epidemic caused by SARS-CoV-1, despite striking similarities of the two viruses. Coronavirus spike protein mediates a crucial step in the infection, i.e., the host cell recognition and viral entry, which starts with binding to host cell angiotensin converting enzyme 2 (ACE2) protein in both viruses. Recent structural and functional studies have shed light on the differential binding behavior of the SARS-CoV-1 and SARS-CoV-2 spike proteins. In particular, cryogenic electron microscopy studies show that ACE2 binding is preceded by a large-scale conformational change in spike protein to expose the receptor binding domain (RBD) to its binding partner. Unfortunately, these studies do not provide detailed information on the dynamics of this activation process. Here, we have used an extensive set of unbiased and biased microsecond-timescale all-atom molecular dynamics (MD) simulations of SARS-CoV-1 and SARS-CoV-2 spike protein ectodomains in explicit solvent to determine the differential behavior of spike protein activation in the two viruses. Our results indicate that the active form of SARS-CoV-2 spike protein is considerably more stable than that of the SARS-CoV-1 spike protein. The deactivation is in part due to interactions between the N-terminal domain (NTD) and the RBD of SARS-CoV-1 spike protein that are absent in SARS-CoV-2. Understanding how coronavirus spike proteins undergo conformational changes prior to binding to host cell ACE2 receptors is key to the development of COVID-19 vaccines and therapeutics, which requires a dynamic rather than a static picture to provide a reliable structure-based drug design framework.